PNPLA3 and metabolic syndrome: A clinical cohort study of the relationships of DAA treatment with PNPLA3 rs738409 and TM6SF2 rs58542926-induced dyslipidemia as well as the improvement of renal function in patients with non-genotype 3 chronic HCV infection is currently in progress (to be published later).